News >

Expert Highlights Early Promise of Selinexor in Myeloma

Angelica Welch
Published: Thursday, Feb 08, 2018

Cristina Gasparetto, MD

Cristina Gasparetto, MD
Combining selinexor with daratumumab (Darzalex) and low-dose dexamethasone demonstrated an impressive safety profile and early signs of clinical activity in a phase Ib/II dose-escalation study of patients with relapsed/refractory multiple myeloma previously treated with proteasome inhibitors and immunomodulatory drugs (IMiDs).

In the small study, investigators enrolled patients on 1 of 2 cohorts of selinexor at 100 mg weekly or 60 mg twice weekly, both with 16 mg/kg of intravenous daratumumab weekly and 40 mg weekly or 20 mg twice weekly of oral dexamethasone.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x